FMP
Belite Bio, Inc
BLTE
NASDAQ
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
56.21 USD
3.17 (5.64%)
Dr. Yu-Hsin Lin M.B.A., Ph.D.
Healthcare
Biotechnology
NASDAQ
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
0001889109
US07782B1044
07782B104
5820 Oberlin Drive
858-246-6240
US
20
Apr 29, 2022
Dr. Nathan L. Mata Ph.D.
Chief Scientific Officer
0
1967
Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D.
Chief Medical Officer & Member of Ophtha...
0
N/A
Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A.
Chief Financial Officer & Director
0
1985
Dr. Yu-Hsin Lin M.B.A., Ph.D.
Chairman of the Board of Directors & Chi...
0
1978
As of December 31, 2024, the total employee count stands at 20, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.